Impulse oscillometry is a better monitor of airway obstruction compared with spirometry in patients with chronic obstructive pulmonary disease.
In a retrospective analysis, researchers examined the efficacy of beta blocker therapy in prolonging patients' lives.
A 3-variable score that encompasses dyspnea score, prednisone use, and prior hospitalization for COPD exacerbations can predict mortality and readmission risk.
A recent study examined whether nebulized glycopyrrolate is safe to use in patients with severe COPD and comorbid cardiovascular risk factors.
Both reduced forced vital capacity and a restrictive spirometry pattern was associated with arterial stiffness in both men and women.
Mortality rates and changes in mortality rates for chronic respiratory diseases in the United States varied by county, sex, and particular disease type.
In contrast to previous study findings, inhaled corticosteroids do not appear to increase risk for pneumonia in patients with COPD with moderate airflow limitation.
Coronary artery calcium may be the best noninvasive risk marker for predicting cardiovascular events in patients with chronic obstructive pulmonary disease.
Long-acting muscarinic antagonists plus long-acting beta-agonists for COPD is associated with fewer exacerbations compared with long-acting beta-agonists plus inhaled corticosteroids.
Patients with COPD who have elevated blood eosinophilic levels may benefit from treatment with mepolizumab.
Current and former smokers with COPD had much higher total airway mucin concentrations compared with patients who had never smoked.
A multidisciplinary palliative care team may significantly benefit patients with chronic obstructive pulmonary disease.
In patients with mild or moderate chronic obstructive pulmonary disease, tiotropium improved the decline in FEV1, as well as quality of life.
Patients with COPD and comorbid cardiovascular disease may benefit from statin treatment depending on their C - reactive protein levels.
After accounting for individual risk factors, living altitude is not associated with variability in COPD prevalence.
Two phase 3 clinical trials examined mepolizumab 100 or 300 mg vs placebo to treat moderate-to-severe COPD exacerbations.
Researchers hypothosized that increased sputum Gammaproteobacteria:Firmicutes ratio may serve as a biomarker to guide antibiotic treatment in COPD.
People with COPD have been found to benefit from statin therapies, with reduced risk of all-cause and pulmonary-related mortality.
Patients with COPD treated with mucolytic agents for at least 1 year were better protected against exacerbations compared with patients treated with placebo.
Questions involving physician-diagnosed COPD have a low sensitivity and a high specificity.
FEV1 was higher in patients who received tiotropium therapy vs those in the placebo group.
Patients with chronic obstructive pulmonary disease, particularly with exacerbations, have an increased risk for diabetes development.
A 2015 update from the 1990 Global Burden of Disease study reveals current prevalence and mortality of asthma and chronic obstructive pulmonary disease.
Study results showed the benefit of single-inhaler triple therapy vs ICS/LABA therapy in COPD.
Researchers found a weak negative association between PCT testing rate and risk-adjusted antibiotic initiation rate.
Recent research suggests that perioperative and postoperative pulmonary rehabilitation improves outcomes in patients undergoing thoracic surgery.
Inhaled corticosteroids for COPD does not increase the risk for fractures when used for short-term periods.
Timely selection and early intervention, attention to comfort, and frequent checks improved outcomes in patients with chronic obstructive pulmonary disease who were treated with noninvasive ventilation.
Chronic obstructive pulmonary disease may be misdiagnosed in patients as a result of errors related to spirometry tests, errors made in primary care, and differential diagnoses, among others.
The rate of forced expiratory volume in one second decline in patients with moderate COPD can be reduced by regular use of fluticasone furoate, either alone or in combination with vilanterol.
Pneumonia primarily affects young children, smokers, adults 65 years and older, and people with COPD.
Occupational exposures are a modifiable risk factor for COPD.
Researchers examined structural social support indicators, including living status, having a partner, number of close friends and relatives, and the presence of a family caregiver.
Cardio- and cerebrovascular events were more common in patients being treated with combination long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) therapies vs LABA/inhaled corticosteroids.
Comparative measures of inspiratory vs expiratory volumes show a penumbra of lung tissue at higher risk of damage from existing COPD.
The first study of antibiotic use in outpatients with COPD exacerbations found that doxycycline plus prednisone did not prolong the time between exacerbations.
Azithromycin therapy is more effective at preventing COPD exacerbations among patients with Helicobacter pylori infection than among those who are H pylori seronegative.
In a real-world study, once-daily, single-inhaler triple therapy reduced COPD exacerbations more than twice-daily double therapy.
The patient presented with obesity and reduction in bilateral hip flexion strength and shoulder abduction.
Chest CT is not currently part of recommended routine COPD care.
Associated cardiovascular side effects of bronchodilators may reduce prescription rates in patients with COPD with comorbid cardiovascular disease.
Odds of ischemic heart disease-related morbidity, mortality increased after new opioid use
Patients with persistent hypercapnia following acute exacerbation of COPD, home noninvasive ventilation with home oxygen therapy prolonged readmission time.
Two phase 3 clinical development programs showed improved breathing in children and adolescents with moderate-to-severe asthma regardless of allergic status.
Multiple studies presented at ATS 2017 indicated that indacaterol/glycoptrrolate inhaler therapy results in clinically significant improvements in COPD-related quality of life.
No difference was noted in all-cause readmission rates in the intervention vs non-intervention groups.
The release of a new autonomous approach for terminating the COPD crisis has been lead by the National Heart, Lung and Blood Institute (NHLBI).
Researchers examined the relationship between COPD and right and left ventricular morphometry to determine which patients may better respond to beta-blocker therapies.
Online pulmonary rehabilitation is non-inferior to face-to-face rehabilitation for patients with COPD, according to research presented at ATS 2017.
A new survey shows that home oxygen services create barriers for patients with lung disease.
The TRINITY study reports the significant benefits to extafine triple therapy taken in a single inhaler compared with tiotropium in chronic obstructive pulmonary disease.
Simulated studies were key to the approval of roflumilast for reducing COPD exacerbations.
Patients with COPD and asthma can be characterized by the presence of allergies and more exacerbation with less eosinophilic inflammation.
Study results suggest that gas trapping, not emphysema, is associated with pulmonary vascular remodeling in COPD.
Combination therapy with an inhaled LABA and inhaled corticosteroid did not affect all-cause mortality in patients with COPD compared with inhaled placebo, LABA alone, or corticosterioid alone.
The National Academies of Sciences, Engineering, and Medicine released a report titled "The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendation for Research."
Demographic, family and social factors are important in the role of empowering elderly patients with chronic obstructive pulmonary disease.
Sunovion announces Utibron Neohaler, an inhalation powder for the long term maintenance treatment of airflow obstruction in COPD patients.
The European Respiratory Society and the American Thoracic Society released clinical guidelines for the treatment of patients with chronic obstructive pulmonary disease exacerbations.
Noninvasive positive-pressure ventilation to clear secretions in patients with acute exacerbations of chronic obstructive pulmonary disease may be more beneficial than conventional mechanical ventilation.
Statin use was associated with a 20% lower risk for all-cause mortality and a 45% lower risk for pulmonary-related mortality.
Patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) had decreased exacerbations after 3 months of commencing budesonide/formoterol treatment.
Morning symptoms are common among patients with chronic obstructive pulmonary disease (COPD) and are frequently associated with limitations of physical activity.
The 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report was released and includes updated recommendations for the diagnosis and management of chronic obstructive pulmonary disease.
Researchers have suggested a new definition for common smoke-related pulmonary disease (CSPD).
The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) effectively indicates mortality risk in patients with intestinal lung disease.
Long-term supplemental oxygen does not provide any benefit for patients with stable chronic obstructive pulmonary disease regarding time of death or first hospitalization.